The FDA-approved prescribing label for Bydureon has a prominent warning stating that the drug caused certain kinds of thyroid tumors in rats at clinically relevant exposures in testing, according to the FDA website.
WSJ: FDA Approves Amylin's Bydureon Diabetes Drug After Delays